CVA
MCID: CRB039
MIFTS: 70

Cerebrovascular Disease (CVA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

MalaCards integrated aliases for Cerebrovascular Disease:

Name: Cerebrovascular Disease 12 56 15
Cerebrovascular Disorders 45 74
Cerebrovascular Accident 12 74
Cerebrovascular Disorder 12 17
Stroke 12 45
Cva 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6713
NCIt 51 C2938 C3390
SNOMED-CT 69 62914000 82797006

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to peripheral artery disease and stroke, ischemic, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Microglia Activation During Neuroinflammation: Overview. The drugs Rivastigmine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 77 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1412)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 32.6 ACE APOB CRP SELP
2 stroke, ischemic 32.4 ACE AGTR1 APOB APOE CRP MTHFR
3 cerebral palsy 32.4 APOE COL4A1 MTHFR
4 grange syndrome 32.3 MTHFR PLAT SELP
5 vascular dementia 32.2 ACE ACHE APOE APP MTHFR NOTCH3
6 binswanger's disease 32.2 ACHE APOE APP NOTCH3
7 peripheral vascular disease 32.2 ACE APOA1 APOB CRP PLAT SELP
8 supranuclear palsy, progressive, 1 32.2 ACHE APOE APP
9 dementia 31.5 ACHE APOE APP NOTCH3
10 cerebral atherosclerosis 31.5 ACE APOA1 APOE MTHFR
11 cerebral amyloid angiopathy, cst3-related 31.5 APOE APP SERPINA3
12 arteriosclerosis 31.4 ACE ADM APOA1 APOB APOE CRP
13 sleep apnea 31.0 ACE APOE CRP
14 carotid stenosis 30.9 ACE APOE CRP MTHFR SELP
15 aortic atherosclerosis 30.7 ACE APOE PON1
16 ischemic heart disease 30.6 ACE AGTR1 APOA1 APOB APOE CRP
17 ischemia 30.6 ACE APP PLAT PON1 SELP
18 hemorrhage, intracerebral 30.6 ACE APOE APP COL4A1 PLAT
19 end stage renal failure 30.6 ACE AGTR1 APOB CRP
20 platelet aggregation, spontaneous 30.6 PLAT SELP SERPINA3
21 atrial fibrillation 30.5 ACE AGTR1 CRP PLAT SELP
22 macular degeneration, age-related, 1 30.5 APOB APOE CRP CX3CR1
23 arteries, anomalies of 30.5 ACE AGTR1 APOA1 APOB APOE CRP
24 pulmonary embolism 30.5 CRP MTHFR PLAT
25 ischemic optic neuropathy 30.4 ACE AGTR1 MTHFR
26 coronary artery anomaly 30.4 ACE AGTR1 APOA1 APOB CRP PLAT
27 intermittent claudication 30.4 ACE CRP SELP
28 atherosclerosis susceptibility 30.4 APOA1 APOB APOE CRP PON1
29 angina pectoris 30.4 ACE CRP PLAT
30 homocysteinemia 30.4 CRP MTHFR MTR
31 lipid metabolism disorder 30.4 ACE APOA1 APOB APOE CRP
32 nonarteritic anterior ischemic optic neuropathy 30.3 ACE AGTR1 MTHFR
33 coronary heart disease 1 30.3 ACE APOA1 APOB APOE CRP CX3CR1
34 carotid artery disease 30.3 ACE APOA1 APOB APOE CRP
35 vitamin b12 deficiency 30.3 MTHFR MTR PON1
36 cerebral hemorrhage 30.3 APOB APP
37 migraine with aura 30.3 ACE MTHFR NOTCH3
38 antiphospholipid syndrome 30.2 MTHFR PLAT SELP
39 arteritic anterior ischemic optic neuropathy 30.1 ACE CRP MTHFR
40 hypertriglyceridemia, familial 30.1 APOA1 APOB APOE
41 renovascular hypertension 30.1 ACE ADM AGTR1
42 carotid artery dissection 30.1 HOTAIR MTHFR PLAT
43 diabetes mellitus, noninsulin-dependent 30.1 ACE AGTR1 APOA1 APOB APOE CRP
44 microvascular complications of diabetes 5 30.1 ACE AGTR1 PON1
45 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 30.1 MTHFR MTR
46 coronary stenosis 30.0 ACE APOA1 APOB APOE CRP PON1
47 dementia, lewy body 30.0 ACHE APOE APP
48 nephrosclerosis 30.0 ACE AGTR1 MTHFR
49 kidney disease 29.9 ACE ADM AGTR1 APOE CRP
50 diabetes mellitus 29.9 ACE AGTR1 APOA1 APOB CRP MEG3

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 40)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Ischemic Heart Disease
Labyrinthitis Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


seizures, tremor, angina pectoris, edema, back pain, pain, chest pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness, transient ischemic attacks, stereotypic symptoms

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 ACE ACHE ADM AGTR1 APOA1 APOB
2 cardiovascular system MP:0005385 10.39 ACE ADM AGTR1 APOA1 APOB APOE
3 behavior/neurological MP:0005386 10.3 ACE ACHE ADM AGTR1 APOE APP
4 growth/size/body region MP:0005378 10.3 ACE ACHE AGTR1 APOB APOE APP
5 cellular MP:0005384 10.28 ADM APOA1 APOB APOE APP COL4A1
6 immune system MP:0005387 10.26 ACE ADM AGTR1 APOB APOE APP
7 hematopoietic system MP:0005397 10.25 ACE ACHE ADM AGTR1 APOE APP
8 mortality/aging MP:0010768 10.25 ACE ACHE ADM AGTR1 APOB APOE
9 integument MP:0010771 10.11 ADM APOA1 APOE APP CX3CR1 MTHFR
10 nervous system MP:0003631 10.06 ACHE AGTR1 APOB APOE APP COL4A1
11 muscle MP:0005369 10.02 ACHE ADM APOB APOE APP COL4A1
12 liver/biliary system MP:0005370 9.98 ACE ADM APOA1 APOB APOE MTHFR
13 reproductive system MP:0005389 9.9 ACE ACHE ADM APOB APOE APP
14 renal/urinary system MP:0005367 9.86 ACE ADM AGTR1 APOE COL4A1 CX3CR1
15 respiratory system MP:0005388 9.5 ACHE ADM APOE COL4A1 NOTCH3 PLAT
16 vision/eye MP:0005391 9.28 ACHE APOB APOE COL4A1 CX3CR1 MTHFR

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 905)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
3
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
4
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable 88150-42-9 2162
5
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
6
Telmisartan Approved, Investigational Phase 4,Phase 3,Not Applicable 144701-48-4 65999
7
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
8
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
9
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
10
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 53123-88-9 46835353 6436030 5284616
11
Everolimus Approved Phase 4,Phase 2,Phase 3,Not Applicable 159351-69-6 6442177 70789204
12
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 73963-72-1 2754
13
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 134523-00-5 60823
14
Perindopril Approved Phase 4,Phase 3,Not Applicable 107133-36-8, 82834-16-0 107807
15
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-93-5 3639
16
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
17
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
18
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
19
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 124-94-7 31307
21
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
22
Valsartan Approved, Investigational Phase 4,Phase 2,Not Applicable 137862-53-4 60846
23
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
24
Nadroparin Approved, Investigational Phase 4,Phase 3
25
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
26
Probucol Approved, Investigational Phase 4 23288-49-5 4912
27
Nimodipine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 66085-59-4 4497
28
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
29
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
31
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Not Applicable 152-72-7 9052 54676537
32
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
33
Nicardipine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55985-32-5 4474
34
alemtuzumab Approved, Investigational Phase 4 216503-57-0
35
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
36
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
37
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
38
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
39
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
40
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 120014-06-4 3152
41
Bupropion Approved Phase 4,Not Applicable 34841-39-9, 34911-55-2 444
42
Varenicline Approved, Investigational Phase 4,Not Applicable 249296-44-4 5310966
43
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
44
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
45
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
46
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
47
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
48
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-41-2 439260
49
Galantamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 357-70-0 9651
50
Edaravone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 89-25-8 70335

Interventional clinical trials:

(show top 50) (show all 5101)
# Name Status NCT ID Phase Drugs
1 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
2 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
3 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
4 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
5 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
6 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
7 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
8 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
9 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Unknown status NCT02594995 Phase 4 NBP
10 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
11 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Unknown status NCT02768571 Phase 4 Cerebrolysin;Placebo
12 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
13 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
14 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
15 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
16 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
17 Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease Unknown status NCT01932203 Phase 4 aspirin;cilostazol
18 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
19 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
20 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
21 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
22 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
23 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
24 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
25 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
26 Botulinum Toxin A for Shoulder Pain After Stroke Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
27 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
28 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
29 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
30 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
31 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
32 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
33 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
34 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
35 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
36 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
37 PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
38 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
39 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
40 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
41 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
42 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
43 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
44 Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Unknown status NCT02224209 Phase 4
45 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
46 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
47 Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy Unknown status NCT01918722 Phase 4 ICH-1(herbal medicine with Hirudo, Tabanus);placebo;ICH-2(herbal medicine without Hirudo, Tabanus)
48 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Unknown status NCT02826200 Phase 4 Acenocoumarol
49 The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage Unknown status NCT01346748 Phase 4 statin
50 A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population Unknown status NCT02618382 Phase 4 Tranexamic Acid

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

42
Brain, Heart, Testes, Endothelial, Bone, Kidney, Bone Marrow

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 2957)
# Title Authors Year
1
Four-Year Experience Using an Advanced Interdisciplinary Hybrid Operating Room : Potentials in Treatment of Cerebrovascular Disease. ( 30630294 )
2019
2
Bell Palsy and the Risk of Cardio-Cerebrovascular Disease: A Population-Based Follow-Up Study. ( 30632167 )
2019
3
Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®. ( 30648358 )
2019
4
Night-time systolic blood pressure and subclinical cerebrovascular disease: the Cardiovascular Abnormalities and Brain Lesions (CABL) study. ( 30649236 )
2019
5
Effect of Interventional Therapy on IL-1β, IL-6, and Neutrophil-Lymphocyte Ratio (NLR) Levels and Outcomes in Patients with Ischemic Cerebrovascular Disease. ( 30664615 )
2019
6
Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: A case report. ( 30680201 )
2019
7
High cholesterol triggers white matter alterations and cognitive deficits in a mouse model of cerebrovascular disease: benefits of simvastatin. ( 30692517 )
2019
8
Cerebrovascular Disease: Primary and Secondary Stroke Prevention. ( 30704682 )
2019
9
Clinical factors influencing the development of extracranial-intracranial bypass graft for steno-occlusive cerebrovascular disease. ( 30717071 )
2019
10
Patients with Acute Ischemic Cerebrovascular Disease with Coronary Artery Stenosis Have More Diffused Cervicocephalic Atherosclerosis. ( 30726790 )
2019
11
Mixed cerebrovascular disease in an elderly patient with mixed vascular risk factors: a case report. ( 30755166 )
2019
12
Cerebrovascular disease burden in late-onset non-lesional focal epilepsy. ( 30776698 )
2019
13
Commentary on "Depression Predicts Delirium After Coronary Artery Bypass Graft Surgery Independent of Cognitive Impairment and Cerebrovascular Disease: An Analysis of the Neuropsychiatric Outcomes After Heart Surgery Study". ( 30777638 )
2019
14
Cerebrovascular Disease in the Young Adult: Examining Melatonin's Possible Multiple Roles. ( 30783379 )
2019
15
Serum klotho: a potential predictor of cerebrovascular disease in hemodialysis patients. ( 30791885 )
2019
16
Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel. ( 30817601 )
2019
17
A nomogram for the prediction of cerebrovascular disease among patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma. ( 30825967 )
2019
18
Predicting asymptomatic coronary artery stenosis by aortic arch plaque in acute ischemic cerebrovascular disease: beyond the cervicocephalic atherosclerosis? ( 30829720 )
2019
19
Assessment of physical activity and cognitive function and their potential correlation in convalescent patients of cerebrovascular disease. ( 30846760 )
2019
20
Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome. ( 30864116 )
2019
21
mTOR in neurological diseases. ( 30867339 )
2019
22
A U-Net Deep Learning Framework for High Performance Vessel Segmentation in Patients With Cerebrovascular Disease. ( 30872986 )
2019
23
Associations of plasma LP(a), Hcy and D-D levels with the subtype of ischemic cerebrovascular disease. ( 30882710 )
2019
24
Lifetime discrimination burden, racial discrimination, and subclinical cerebrovascular disease among African Americans. ( 30474995 )
2019
25
Circulating inflammatory biomarkers are related to cerebrovascular disease in older adults. ( 30568999 )
2019
26
Cost-effectiveness of home blood pressure telemonitoring and case management in the secondary prevention of cerebrovascular disease in Canada. ( 30570200 )
2019
27
The relationship between obesity subtypes based on BMI and cardio-cerebrovascular disease. ( 30622319 )
2019
28
Cerebrovascular disorders associated with genetic lesions. ( 30327838 )
2019
29
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( 29395638 )
2018
30
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. ( 29600737 )
2018
31
Prevalence, Risk Factors, Outcomes, and Treatment of Obstructive Sleep Apnea in Patients with Cerebrovascular Disease: A Systematic Review. ( 29555400 )
2018
32
Under-utilization of statin medications in patients with peripheral artery disease or cerebrovascular disease. ( 29600738 )
2018
33
Cerebrovascular Disease Knowledge Portal: An Open-Access Data Resource to Accelerate Genomic Discoveries in Stroke. ( 29335331 )
2018
34
Systematic investigation of the Erigeron breviscapus mechanism for treating cerebrovascular disease. ( 29783016 )
2018
35
Association between primary SjAPgren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis. ( 29600936 )
2018
36
Revascularization experience and results in ischaemic cerebrovascular disease: Moyamoya disease and carotid occlusion. ( 29550248 )
2018
37
Improvement of postoperative cognitive dysfunction and attention network function of patients with ischemic cerebrovascular disease via dexmedetomidine. ( 29599834 )
2018
38
Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults. ( 29310864 )
2018
39
The effect of rheumatoid arthritis on the risk of cerebrovascular disease and coronary artery disease in young adults. ( 29861211 )
2018
40
Controversies in cerebrovascular disease: High or low doses of recombinant tissue plasminogen activator to treat acute stroke? A literature review. ( 29891335 )
2018
41
Association Between Heart Rate and Subclinical Cerebrovascular Disease in the Elderly. ( 29284731 )
2018
42
High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease. ( 29769642 )
2018
43
Survival after in-hospital cardiac arrest among cerebrovascular disease patients. ( 29789199 )
2018
44
Migraine and cerebrovascular disease: still a dangerous connection? ( 29904830 )
2018
45
More Than Meets the Eye: Cerebrovascular Disease in Sickle Cell Disease Is About More Than Sickling. ( 29695469 )
2018
46
Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable. ( 29696578 )
2018
47
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. ( 29311290 )
2018
48
Preeclampsia Increases the Incidence of Postpartum Cerebrovascular Disease in Korean Population. ( 29349936 )
2018
49
Cognitive deterioration in schizophrenia: aging and cerebrovascular disease. ( 29936917 )
2018
50
Lower body functioning and correlates among older American Indians: The Cerebrovascular Disease and Its Consequences in American Indians Study. ( 29304750 )
2018

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 APOA1 APOB APOE MTHFR MTR
2
Show member pathways
11.72 APP COL4A1 CX3CR1 PLAT
3
Show member pathways
11.57 APOA1 APOB APOE COL4A1
4
Show member pathways
11.56 APOA1 APOB APOE CRP MTHFR MTR
5 11.23 APOB PLAT SELP
6 10.76 ACE APOE APP CX3CR1
7 10.69 ACE APP PLAT
8 10.51 HOTAIR MEG3

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.88 APOA1 APOB APOE APP COL4A1
2 collagen-containing extracellular matrix GO:0062023 9.85 APOA1 APOE COL4A1 PLAT SERPINA3
3 early endosome GO:0005769 9.84 APOA1 APOB APOE APP
4 blood microparticle GO:0072562 9.81 APOA1 APOE PON1 SERPINA3
5 extracellular region GO:0005576 9.77 ACE ACHE ADM APOA1 APOB APOE
6 high-density lipoprotein particle GO:0034364 9.61 APOA1 APOE PON1
7 very-low-density lipoprotein particle GO:0034361 9.58 APOA1 APOB APOE
8 endosome lumen GO:0031904 9.56 APOB APP
9 synaptic cleft GO:0043083 9.55 ACHE APOE
10 endocytic vesicle lumen GO:0071682 9.54 APOA1 APOB APOE
11 spherical high-density lipoprotein particle GO:0034366 9.52 APOA1 PON1
12 low-density lipoprotein particle GO:0034362 9.5 APOA1 APOB APOE
13 discoidal high-density lipoprotein particle GO:0034365 9.49 APOA1 APOE
14 extracellular space GO:0005615 9.44 ACE ACHE ADM APOA1 APOB APOE
15 chylomicron GO:0042627 9.43 APOA1 APOB APOE
16 intermediate-density lipoprotein particle GO:0034363 9.33 APOA1 APOB APOE

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.9 APOA1 APOB APOE APP
2 cholesterol homeostasis GO:0042632 9.82 APOA1 APOB APOE
3 platelet degranulation GO:0002576 9.81 APOA1 APP SELP SERPINA3
4 response to wounding GO:0009611 9.79 ACHE ADM CX3CR1
5 retinoid metabolic process GO:0001523 9.74 APOA1 APOB APOE
6 triglyceride catabolic process GO:0019433 9.67 APOA1 APOB APOE
7 high-density lipoprotein particle remodeling GO:0034375 9.66 APOA1 APOE
8 positive regulation of lipid biosynthetic process GO:0046889 9.66 APOA1 APOE
9 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.65 AGTR1 APOB
10 positive regulation of cholesterol efflux GO:0010875 9.65 APOE PON1
11 regulation of blood vessel diameter GO:0097746 9.65 ACE AGTR1
12 cholesterol efflux GO:0033344 9.65 APOA1 APOB APOE
13 high-density lipoprotein particle assembly GO:0034380 9.64 APOA1 APOE
14 phospholipid efflux GO:0033700 9.63 APOA1 APOE
15 amyloid precursor protein metabolic process GO:0042982 9.63 ACHE APOE
16 lipoprotein metabolic process GO:0042157 9.63 APOA1 APOB APOE
17 methionine biosynthetic process GO:0009086 9.62 MTHFR MTR
18 high-density lipoprotein particle clearance GO:0034384 9.62 APOA1 APOE
19 very-low-density lipoprotein particle remodeling GO:0034372 9.61 APOA1 APOE
20 artery morphogenesis GO:0048844 9.61 APOB APOE NOTCH3
21 chylomicron remnant clearance GO:0034382 9.59 APOB APOE
22 regulation of Cdc42 protein signal transduction GO:0032489 9.58 APOA1 APOE
23 regulation of cholesterol transport GO:0032374 9.58